Theranos ended 2016 with $200 million in cash left in the till — but when you subtract off the uncertain cost of bringing a consumer-focused blood tester to market and handling its legal matters — will that will be enough?

from Forbes – Tech http://ift.tt/2lenfqo
via IFTTT